Mebeverine
From Wikipedia, the free encyclopedia
 |
|
 |
|
|
Mebeverine
|
|
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Mebeverine HCI is a musculotropic antispasmodic drug without atropic side-effects whose major therapeutic role is in the treatment of irritable bowel syndrome. It is also indicated for treatment of gastrointestinal spasm secondary to organic disorder. It was first registered in 1965 and manufacture by Solvay Pharmaceuticals.
Mebeverine HCI presented in tablets (100mg or 135mg), capsules (200mg slow release), and liquid (10mg/ml).
[edit] Mode of Action
Mebeverine HCI belongs to a group of compounds called musculotropic antispasmodics. These compounds act directly on the gut muscles at the cellular level to relax them. Mebeverine is also an inhibitor of calcium-depot replenishment (prokinetic effect). Therefore, mebeverine has dual mode of action which normalize the small bowel motility.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
